In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ...
Nektar Therapeutics Inc (NASDAQ:NKTR) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data from Benzinga Pro. The company released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results